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Abstracts / Biol Blood Marrow Transplant 20 (2014) S104eS127S116treatment cycles was 15 (range, 1-16) and 159 pts (49%)
received 16 cycles. A total of 61 pts (19%) discontinued
treatment due to adverse events. Thirty-ﬁve pts (11%) are
known to have died; 31 deaths occurred after disease pro-
gression. One death occurred within 30 days of last dose and
was considered disease-related.
Conclusions: Based upon a planned interim safety and fu-
tility analysis, the IDMC recommended that the AETHERA
trial continue per protocol.149
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High Dose melphalan (200 mg/m2, Mel200) is the standard
conditioning for autologous stem-cell transplant (ASCT) in
multiple myeloma (MM) patients. Forty percent of MM pa-
tients experience some degree of renal insufﬁciency.
Although common practice, there is no standard for dose
reduction in melphalan due to renal impairment. In addition,
there is no clear correlation between melphalan pharmaco-
kinetics in renal failure and outcome in these patients. Here
we report the impact of renal impairment on response and
toxicity outcomes in patients receiving Mel200 as part of
ASCT.
We identiﬁed 111 patients who received Mel200 and ASCT
between 2001 and 2012 at the University of Illinois. Overall,
the majority of patients were African American (60%). Pa-
tients were stratiﬁed by renal function (n¼35 CrCl <60 ml/
min and n¼76 CrCl  60 ml/min). Baseline characteristics
were equal between the 2 groups aside from age (63.2 years
 8.8 vs. 56.8  8.8. P¼.0004). Patients with renal failure
experienced a signiﬁcantly longer time to engraftment
(12.2 days  3.51 vs. 10.6 days  1.7, P¼.0025) and duration
of diarrhea (6.6 days  6.3 vs. 4 days  3.7. P¼.007). Length
of hospital stay was similar between the two groups (17.6
days  4.5 vs. 16.25 days  5.2. P¼.21). Patients with renal
failure spent an average of 10.6 days on total parenteral
nutrition, compared to 7.27 days in patients with normal
renal function (P¼ns). There were no deaths related to
transplant related mortality in either group. . There was no
difference in response rates between the 2 groups in
terms of complete response (50% in CrCl<60ml/min vs. 40%
in Cr Cl > 60ml/min,P¼ns) or overall response rate at day
+90 (75% in CrCl<60ml/min vs. 100% in Cr Cl > 60ml/
min,P¼ns).
This data demonstrates an increase in drug-related toxicities
of diarrhea, and time on TPN in patients with renal impair-
ment conditioned with HD Mel. We hypothesize that this is
due to reduced renal drug clearance. In addition, longer time
to engraftment in the renal failure group may be a result of
greater overall melphalan exposure. In light of the large
numbers of patients impacted by this data, we suggest that
this would be an ideal patient group for the development of
pharmacokinetic based strategies for individual patient
dosing.150
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Background: Pneumocystis jirovecii pneumonia (PJP) is a
potentially life-threatening disease in immunocompromised
patients. The at-risk population includes patients with HIV
infection and low CD4 counts, hematological malignancies,
hematopoietic stem cell (HSC) and solid organ transplant
recipients, and patients receiving glucocorticoids or other
immunomodulatory agents. The highest-risk group of
immunocompromised patients tends to be those with HIV
(human immunodeﬁciency virus) infection, where PJ follows
an indolent course. However, in non-HIV immunocompro-
mised patients, such as HSC transplant recipients, the
infection tends to present with respiratory failure. The inci-
dence of PJP in autologous BMT (bone marrow transplant)
has not been clearly determined, and the indication for
prophylaxis in this setting remains unclear. In this study we
evaluate the incidence of PJP over a 10-year period in re-
cipients of autologous transplants.
Methods: A retrospective analysis of 1191 consecutive
autologous HSC transplants (1-75 years) performed between
1/1/2000 and 6/30/2011 at the University of Michigan BMT
Program. The data was obtained from BMT Program Data-
base at The University of Michigan Comprehensive Cancer
Center. The diagnosis of PJP was established by bronchoscopy
with brochoaveolar lavage (BAL) with polymerase chain re-
action (PCR). We analyzed the following risk factors for the
development of PJP: diabetes, glucocorticoids, infections,
cutaneous T-cell lymphoma, hypertension, and seizure
disorder.
Results: A total number of 5 PJ infections were diagnosed
during study period, resulting in a cumulative incidence of
0.42% (95%CI [0.136449%–0.976969%]) over 10 year period.
All cases occurred between 2001 and 2006, and 3 months or
later following transplantation. Most patients (n¼4) were
older than 50 years old, and all of them were on steroids.
Diagnoses included non-Hodgkin’s lymphoma (n¼3),
Hodgkin’s lymphoma (n¼1) and multiple myeloma (n¼1).
Conditioning regimen was BEAM (BCNU, etoposide, cytar-
abine, melphalan, n¼4) and high dose melphalan (n¼1).
Only 2/5 patients were neutropenic at the time of the
pneumonia, and this did not correlate with the CD34+ cell
infused, which was 2.2x10E6/kg for all patients. Four pa-
tients were on corticosteroids for relapsed lymphoma (n¼2),
ITP (n¼1), BCNU pneumonitis (n¼1). The remainder patient
was on ﬂorinef and was coinfected with candida and herpes
virus. There were no particular comorbidities associated
with the diagnosis of PJ pneumonia. One patient died of PJ,
the remainder were treated successfully.
Conclusions: Our retrospective analysis of a large cohort of
autologous transplant recipients reveals an extremely low
